OR Royalties (OR) Expected to Announce Earnings on Wednesday

OR Royalties (NYSE:OR) will likely be posting its Q4 2025 results before the market opens on Wednesday, February 18th. Analysts expect the company to announce earnings of $0.31 per share for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 19, 2026 at 10:00 AM ET.

OR Royalties Price Performance

NYSE OR opened at $42.98 on Wednesday. The business’s 50-day moving average is $38.74 and its 200 day moving average is $35.50. OR Royalties has a 1 year low of $17.55 and a 1 year high of $47.75. The stock has a market capitalization of $8.04 billion, a PE ratio of 54.41 and a beta of 0.76.

Institutional Trading of OR Royalties

A number of institutional investors have recently modified their holdings of the company. Goldman Sachs Group Inc. grew its stake in OR Royalties by 152.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,256,583 shares of the basic materials company’s stock worth $26,539,000 after buying an additional 758,815 shares during the last quarter. Geode Capital Management LLC raised its position in OR Royalties by 2.7% during the second quarter. Geode Capital Management LLC now owns 92,267 shares of the basic materials company’s stock valued at $2,384,000 after acquiring an additional 2,459 shares in the last quarter. Cetera Investment Advisers increased its holdings in shares of OR Royalties by 3.5% during the 2nd quarter. Cetera Investment Advisers now owns 13,147 shares of the basic materials company’s stock valued at $337,000 after purchasing an additional 440 shares in the last quarter. JPMorgan Chase & Co. grew its position in shares of OR Royalties by 58.3% during the 2nd quarter. JPMorgan Chase & Co. now owns 205,176 shares of the basic materials company’s stock valued at $5,275,000 after acquiring an additional 75,596 shares during the period. Finally, Gamco Investors INC. ET AL purchased a new position in shares of OR Royalties during the 2nd quarter valued at approximately $1,051,000. 68.52% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. Wall Street Zen raised OR Royalties from a “buy” rating to a “strong-buy” rating in a research report on Monday, January 19th. Canadian Imperial Bank of Commerce restated an “outperform” rating on shares of OR Royalties in a research note on Wednesday, February 4th. Zacks Research upgraded OR Royalties from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 4th. Canaccord Genuity Group upgraded OR Royalties from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 22nd. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of OR Royalties in a report on Monday, December 29th. Two analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $38.25.

About OR Royalties

OR Royalties PLC (NYSE: OR) is a closed-ended investment company that specializes in acquiring and managing royalty interests in life science and pharmaceutical products. The company provides capital to biotechnology, specialty pharmaceutical and medical device companies in exchange for a share of future sales revenues. By focusing on royalties secured against marketed products, OR Royalties aims to deliver income and growth potential while minimizing the development and commercialization risks typically associated with direct equity stakes.

The company’s core activities include sourcing royalty transactions, structuring bespoke financing solutions and actively monitoring a diversified portfolio of assets.